14 research outputs found
N-glycoproteins have a major role in mgl binding to colorectal cancer cell lines: Associations with overall proteome diversity
Colorectal cancer (CRC) is the second-leading cause of cancer death worldwide due in part to a high proportion of patients diagnosed at advanced stages of the disease. For this reason, many efforts have been made towards new approaches for early detection and prognosis. Cancer-associated aberrant glycosylation, especially the Tn and STn antigens, can be detected using the macrophage galactose-type C-type lectin (MGL/CLEC10A/CD301), which has been shown to be a promising tool for CRC prognosis. We had recently identified the major MGL-binding glycoproteins in two high-MGL-binding CRC cells lines, HCT116 and HT29. However, we failed to detect the presence of O-linked Tn and STn glycans on most CRC glycoproteins recognized by MGL. We therefore investigated here the impact of N-linked and O-linked glycans carried by these proteins for the binding to MGL. In addition, we performed quantitative proteomics to study the major differences in proteins involved in glycosylation in these cells. Our results showed that N-glycans have a significant, previously underestimated, importance in MGL binding to CRC cell lines. Finally, we highlighted both common and cell-specific processes associated with a high-MGL-binding phenotype, such as differential levels of enzymes involved in protein glycosylation, and a transcriptional factor (CDX-2) involved in their regulation
Quantitative proteomics of small numbers of closely-related cells: Selection of the optimal method for a clinical setting
Mass spectrometry (MS)-based proteomics profiling has undoubtedly increased the knowledge about cellular processes and functions. However, its applicability for paucicellular sample analyses is currently limited. Although new approaches have been developed for single-cell studies, most of them have not (yet) been standardized and/or require highly specific (often home-built) devices, thereby limiting their broad implementation, particularly in non-specialized settings. To select an optimal MS-oriented proteomics approach applicable in translational research and clinical settings, we assessed 10 different sample preparation procedures in paucicellular samples of closely-related cell types. Particularly, five cell lysis protocols using different chemistries and mechanical forces were combined with two sample clean-up techniques (C18 filter- and SP3-based), followed by tandem mass tag (TMT)-based protein quantification. The evaluation was structured in three phases: first, cell lines from hematopoietic (THP-1) and non-hematopoietic (HT-29) origins were used to test the approaches showing the combination of a urea-based lysis buffer with the SP3 bead-based clean-up system as the best performer. Parameters such as reproducibility, accessibility, spatial distribution, ease of use, processing time and cost were considered. In the second phase, the performance of the method was tested on maturation-related cell populations: three different monocyte subsets from peripheral blood and, for the first time, macrophages/microglia (MAC) from glioblastoma samples, together with T cells from both tissues. The analysis of 50,000 cells down to only 2,500 cells revealed different protein expression profiles associated with the distinct cell populations. Accordingly, a closer relationship was observed between non-classical monocytes and MAC, with the latter showing the co-expression of M1 and M2 macrophage markers, although pro-tumoral and anti-inflammatory proteins were more represented. In the third phase, the results were validated by high-end spectral flow cytometry on paired monocyte/MAC samples to further determine the sensitivity of the MS approach selected. Finally, the feasibility of the method was proven in 194 additional samples corresponding to 38 different cell types, including cells from different tissue origins, cellular lineages, maturation stages and stimuli. In summary, we selected a reproducible, easy-to-implement sample preparation method for MS-based proteomic characterization of paucicellular samples, also applicable in the setting of functionally closely-related cell populations
Supplementary Figure S6 from Neoantigen Targetability in Progressive Advanced Melanoma
Expression of tumor associated antigens in early and later metastatic lesions.</p
Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma
Eluted tumor-associated antigen-derived peptides.</p
Supplementary Figure S5 from Neoantigen Targetability in Progressive Advanced Melanoma
Putative neoantigens in early and later metastatic lesions.</p
Supplementary Figure S1 from Neoantigen Targetability in Progressive Advanced Melanoma
Immunohistochemical staining of proteins involved in T cell recognition and/or inhibition.</p
Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
Tumor characteristics.</p
Supplementary Figure S3 from Neoantigen Targetability in Progressive Advanced Melanoma
T cell recognition of melanoma cell lines derived from early and later metastatic lesions.</p
Supplementary Figure S2 from Neoantigen Targetability in Progressive Advanced Melanoma
HLA class I and II expression on melanoma cell lines derived from early and later metastatic lesions.</p
Supplementary Methods S1 from Neoantigen Targetability in Progressive Advanced Melanoma
More detailed information on: 1) Immune-fluorescent staining, 2) Mass spectrometry, 3) MLTC and TIL cultures.</p